The Global Fund, PEPFAR, CIFF, and BMGF are collaborating to provide affordable access to lenacapavir for HIV prevention, aiming to reach at least 2 million people in three years. Gilead Sciences’ lenacapavir is showing promise in preventing new HIV infections and has been licensed for manufacturing in low- and lower-middle-income countries. The goal is to accelerate progress towards ending HIV/AIDS as a public health threat by 2030 through widespread access to this innovative treatment.
Full Article
‘I felt an unspoken pressure to smile’
Faith, a 24-year-old woman in Kenya, faces pressure to conform and be agreeable in her workplace, reflecting a broader issue of "likeability labour" where women feel compelled to prioritize being liked over expressing their opinions. Research shows significant barriers for women in advancing to leadership roles, with 50% in entry-level positions dropping to 26% at senior levels, highlighting systemic inequalities in corporate environments. Want More Context? 🔎
Read more